SynDevRx Receives $1,103,575 New Funding Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    One Broadway 14th Floor Cambridge, MA 02142 USA
  • Company Description
    Our mission is to improve human health by developing polymeric prodrugs which deliver MetAP2 inhibitors to diseased tissues. The first two drug candidates we are developing have been previously shown to shrink tumors, inhibit angiogenesis and prevent metastasis in early clinical trials.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds purposes were not disclosed. 38 investors participated in the offering as amended. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
  • M&A Terms
  • Venture Investor

Trending on Xconomy